Agreement reinforces both companies' commitment to developing
and bringing innovative biological solutions to farmers
BASEL,
Switzerland and REHOVOT, Israel, Feb. 20,
2024 /PRNewswire/ -- Syngenta Crop Protection,
a leader in agricultural innovation, and Lavie Bio Ltd., a
leading ag-biologicals company and a subsidiary of Evogene
Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced an agreement
for the discovery and development of new biological insecticidal
solutions. The collaboration will leverage Lavie Bio's unique technology platform to
rapidly identify and optimize bio-insecticide candidates, as well
as Syngenta's extensive global research, development and
commercialization capabilities.
Insects pose a major challenge to the health of crops worldwide,
directly injuring plants as they feed on the plant's stems, fruit
and roots, as well as indirectly by transmitting bacterial, viral
and fungal infections to crops - costing the global economy an
estimated $70 billion a year,
according to the UN's Food and Agriculture
Organization[1]. Experts predict such losses will worsen
with global warming widening the spread of invasive insect risk and
rising resistance to available insecticides.
"Syngenta is a leader in advancing sustainable agriculture and
we are thrilled to collaborate with Lavie
Bio in biocontrol innovation and bring novel modes of action
in the growers' toolbox to combat insect resistance," said
Camilla Corsi, Global Head of
Research at Syngenta Crop Protection. "This collaboration
underscores Syngenta's commitment to collaborating with
cutting-edge agricultural technology companies, merging digital and
experimental approaches to accelerate and diversify
innovation."
"We're excited to collaborate with Syngenta, a world leader in
agricultural innovation," said Amit
Noam, CEO of Lavie Bio.
"Both companies share a mutual commitment to sustainable farming,
and together, we aim to develop an impactful bio-insecticide
product. Lavie Bio's unique
computational capabilities and Syngenta's vast experience in
developing and commercializing innovative products make this
partnership significant. We enthusiastically look forward to
joining forces to achieve the mutual task of insect management in
agriculture."
About Syngenta Crop Protection
Syngenta Crop Protection is a leader in agricultural innovation,
bringing breakthrough technologies and solutions that enable
farmers to grow productively and sustainably. We offer a leading
portfolio of crop protection solutions for plant and soil health,
as well as digital solutions that transform the decision-making
capabilities of farmers. Our 17,900 employees serve to advance
agriculture in more than 90 countries around the world. Syngenta
Crop Protection is headquartered in Basel, Switzerland, and is part of the
Syngenta Group. Follow us on Twitter at
http://www.twitter.com/Syngenta,
http://www.twitter.com/SyngentaUS and on LinkedIn at
http://www.linkedin.com/company/syngenta
Contact
Michelle Ng
Media Relations, Syngenta Group
michelle.ng@syngenta.com
About Lavie Bio Ltd.:
Lavie Bio, a subsidiary of
Evogene Ltd., aims to improve food quality, sustainability, and
agriculture productivity through the introduction of
microbiome-based ag-biological products. Lavie Bio utilizes a proprietary computational
predictive platform, the BDD platform, powered by Evogene's
proprietary MicroBoost AI tech-engine, harnessing the power
of big data, artificial intelligence, and advanced informatics, for
the discovery, optimization and development of bio-stimulant and
bio-pesticide products.
For more information, please visit www.lavie-bio.com.
About Evogene Ltd.:
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
the probability of success while reducing development time and
cost. Evogene established three unique tech-engines -
MicroBoost AI, ChemPass
AI and GeneRator AI – leveraging Big Data
and Artificial Intelligence and incorporating deep
multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of
products based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus,
medical cannabis products by Canonic and castor varieties, for the
biofuel and other industries, by Casterra.
For more information, please visit: www.evogene.com.
Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901
Lavie Bio and Evogene's
Forward-Looking Statements:
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "hopes" "intends",
"anticipates", "plans", "believes", "scheduled", "estimates",
"demonstrates" or words of similar meaning. For example, Syngenta,
Evogene and its subsidiaries are using forward-looking statement in
this press release when they discuss Lavie
Bio's ability to rapidly identify and optimize
bio-insecticide candidates, the ability of the parties to bring
novel modes of action in the growers' toolbox to combat insect
resistance and to develop impactful bio-insecticide product. Such
statements are based on current expectations, estimates,
projections and assumptions, describe opinions about future events,
involve certain risks and uncertainties which are difficult to
predict and are not guarantees of future performance. Therefore,
actual future results, performance or achievements of Evogene and
its subsidiaries may differ materially from what is expressed or
implied by such forward-looking statements due to a variety of
factors, many of which are beyond the control of Evogene and its
subsidiaries, including, without limitation, the current war
between Israel and Hamas and any
worsening of the situation in Israel such as further mobilizations or
escalation in the northern border of Israel, and those risk factors contained in
Evogene's reports filed with the applicable securities authority.
In addition, Evogene and its subsidiaries rely, and expect to
continue to rely, on third parties to conduct certain activities,
such as their field-trials and pre-clinical studies, and if these
third parties do not successfully carry out their contractual
duties, comply with regulatory requirements or meet expected
deadlines, Evogene and its subsidiaries may experience significant
delays in the conduct of their activities. Evogene and its
subsidiaries disclaim any obligation or commitment to update these
forward-looking statements to reflect future events or developments
or changes in expectations, estimates, projections, and
assumptions.
Syngenta's Cautionary Statement Regarding Forward-Looking
Statements
This document may contain forward-looking statements, which
can be identified by terminology such as 'expect', 'would', 'will',
'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on
track' and similar expressions. Such statements may be subject to
risks and uncertainties that could cause the actual results to
differ materially from these statements. For Syngenta, such risks
and uncertainties include risks relating to legal proceedings,
regulatory approvals, new product development, increasing
competition, customer credit risk, general economic and market
conditions, compliance and remediation, intellectual property
rights, implementation of organizational changes, impairment of
intangible assets, consumer perceptions of genetically modified
crops and organisms or crop protection chemicals, climatic
variations, fluctuations in exchange rates and/or commodity prices,
single source supply arrangements, political uncertainty, natural
disasters, and breaches of data security or other disruptions of
information technology. Syngenta assumes no obligation to update
forward-looking statements to reflect actual results, changed
assumptions or other factors.
©2024 Syngenta. Rosentalstrasse 67, 4058 Basel, Switzerland.
[1] https://www.fao.org/3/i6583e/i6583e.pdf
Logo - https://mma.prnewswire.com/media/945133/lavie_bio.jpg
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
Logo - https://mma.prnewswire.com/media/2343329/Syngenta.jpg
View original
content:https://www.prnewswire.com/news-releases/syngenta-and-lavie-bio-announce-partnership-to-discover-and-develop-novel-bio-insecticide-302065937.html
SOURCE Lavie Bio; Syngenta Crop
Protection